• Contact
Friday, June 20, 2025
Register
Login
European Press
Advertisement
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

PhaseV scores $50M for AI clinical trial platform

13 May 2025
in Health
Reading Time: 1 min read
A A
PhaseV scores M for AI clinical trial platform
ShareShareShareShareShare


Israeli startup PhaseV, an AI-enabled clinical development company for life sciences, has secured $50 million in Series A funding in a round co-led by Accel and Insight Partners. 
Existing investors Viola Ventures, LionBird and EXOR also participated in the round. 
The round brings the company’s total raise to $65 million. 
WHAT IT DOES
PhaseV offers biopharma sponsors and CROs with AI- and ML-enabled insights on clinical operations, causal disease modeling, uncovering treatment response patterns in complex heterogeneity data and identifying patient subgroups for precision medicine. 
“The pharma industry is at a critical crossroads, as traditional approaches to designing and executing clinical trials struggle to meet growing demands for speed, cost-efficiency and higher success rates,” Raviv Pryluk, CEO and cofounder of PhaseV, said in a statement. 
“This funding fuels our mission to support more pharma, biotech and CROs in embracing AI and machine learning to unlock the next era of clinical development. Our solutions deliver clear ROI by increasing trial success rates, reducing costs and accelerating time to market.”
MARKET SNAPSHOT
PhaseV touts that it works with over 30 global pharma companies that use its product for clinical development. 
In 2023, the company raised $15 million in funding.
The startup has established numerous partnerships with life sciences-focused companies.
Earlier this year, PhaseV announced a collaboration with GI-focused clinical research organization Alimentiv. 
Last year, the company partnered with global biometric CRO Quanticate, clinical-stage drug development company NeuroSense Technologies, and oncology- and hematology-focused CRO iOMEDICO. 

Credit: Source link

Related Posts:

  • PhaseV scores M for AI clinical trial platform
    PhaseV scores $50M for AI clinical trial platform
  • Plenful scores $50M and more funding news
    Plenful scores $50M and more funding news
  • Carta Healthcare raises $18.25M to expand AI clinical data platform
    Carta Healthcare raises $18.25M to expand AI…
  • ConcertAI, Bayer join forces to advance precision oncology
    ConcertAI, Bayer join forces to advance precision oncology
ShareTweetSendPinShare
Previous Post

Celebrity Traitors full official lineup, prize money, and launch date finally revealed

Next Post

Latest news bulletin | April 29th – Morning

Next Post
Latest news bulletin | April 29th – Morning

Latest news bulletin | April 29th – Morning

Recommended

‘It’s not something I’ll be repeating’

‘It’s not something I’ll be repeating’

8 June 2025
VidCon 2025: Hank Green and other creators reflect on YouTube’s changes

VidCon 2025: Hank Green and other creators reflect on YouTube’s changes

20 June 2025
Oura Ring vs. Whoop: What’s the best fitness tracker?

Oura Ring vs. Whoop: What’s the best fitness tracker?

21 May 2025
Coronation Street’s Craig Tinker deserved a happier ending after 14 years in soap

Coronation Street’s Craig Tinker deserved a happier ending after 14 years in soap

21 May 2025
Calm expands mental health support app internationally

Calm expands mental health support app internationally

3 June 2025
European Press

European-press.com shares the latest news from Europe and around the world. It covers topics such as business, technology, sports, health, entertainment, and lifestyle. Feel free to get in touch with us!

Disclaimer  Privacy Policy – EU  Imprint 

Contact Us

What’s New Here!

  • Wine shortage fears after bottling workers go on strike at key UK facility
  • Carl Sagan gets his moment at the movies thanks to ‘Elio’ and ‘The Life of Chuck’
  • How can Morocco support the future of Europe’s economy? | AMDIE | The Big Question
  • Emma Raducanu’s stalker prevented from buying Wimbledon tickets

Subscribe to Our Newsletter

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Translate »
European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
×